You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
The company announced that it is planning to submit an NDA for the drug in RET-mutant medullary thyroid cancer.
The randomized, 400-patient trial will compare selpercatinib to chemotherapy for first-line treatment of medullary thyroid cancer.
The firms plan to use Thermo Fisher's Oncomine Dx Target test to identify cancer patients with RET alterations who might benefit from Lilly's LOXO-292.
The groups will use Helomics' artificial intelligence-based platform to develop tools to provide predictive therapeutic recommendations for ovarian and thyroid cancers.